This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

New York, New York--(Newsfile Corp. - February 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conting ...

SAN FRANCISCO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 (N.D. Cal.), seeks to recover losses for investors who purchased CORT common stock between October 31, 2024, and December 30, 2025. The fi ...

Key Takeaways Perrigo's Q4 EPS fell 17.2% to 77 cents as Infant Formula weakness hit sales and margins.PRGO guided All In 2026 sales down 1.5%-5.5% and EPS of $2.00-$2.30, below expectations.Perrigo will restructure into Self Care, Specialty Care and Infant Formula segments in 2026.Perrigo (PRGO) reported adjusted earnings per share (EPS) of 77 cents for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 80 cents. The reported figure decreased 17.2% year over year, primarily due to hea ...

Key Takeaways TG Therapeutics reported Q4 EPS of 14 cents, missing estimates despite 78% revenue growth.Briumvi recorded $189.1M in Q4 revenues, with U.S. net sales rising 76% Y/Y and 20% sequentially.TGTX reaffirmed 2026 revenue guidance of $875M-$900M, with Briumvi sales expected to be $825-$850M.TG Therapeutics (TGTX) reported earnings of 14 cents per share for the fourth quarter of 2025, which substantially missed the Zacks Consensus Estimate of 35 cents. The company had reported earnings of 15 cents pe ...

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with 80% of patients achieving a PSA50 response at the expansion dose. ...

Merck to lay off around 150 employees at US site amid slump in Gardasil sales | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo [Purchase Licensing Rights, opens new tab]- Companies[Merck & Co Inc]FollowFeb 27 (Reuters) - Merck [(MRK.N), opens new tab] will lay off about 150 employees across its fa ...

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.Xeris Biopharma Holdings stock is taking a hit today. What’s weighing on XERS shares?Lawsuit Targets Two Pharmaceutical CompaniesThe lawsuit, filed by Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, targets unauthorized generic versions of Recorlev. The lawsuit names Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC as the ...

Ensysce Biosciences (NASDAQ:ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value.The company on Wednesday announced that its Board of Directors is exploring a range of strategic alternatives, which may include partnerships, licensing arrangements, or asset sales.The strategic review is intended to support the advancement of its proprietary technologies, specifically the TAAP and MPAR platforms.“Our technologies were designed to fu ...

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that ...